Significance of Lavage Cytology in Advanced Gastric Cancer Patients
Background Lavage cytology positive (Cy1) is well known as a poor prognostic factor in advanced gastric cancer patients. However, the optimal therapeutic strategy for patients with Cy1 has not yet been established. The aim of this study was to evaluate the clinical significance of Cy1 for the purpos...
Gespeichert in:
| Veröffentlicht in: | World journal of surgery 2010-03, Vol.34 (3), p.563-568 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 568 |
|---|---|
| container_issue | 3 |
| container_start_page | 563 |
| container_title | World journal of surgery |
| container_volume | 34 |
| creator | Fukagawa, Takeo Katai, Hitoshi Saka, Makoto Morita, Shinji Sasajima, Yuko Taniguchi, Hirokazu Sano, Takeshi Sasako, Mitsuru |
| description | Background
Lavage cytology positive (Cy1) is well known as a poor prognostic factor in advanced gastric cancer patients. However, the optimal therapeutic strategy for patients with Cy1 has not yet been established. The aim of this study was to evaluate the clinical significance of Cy1 for the purpose of establishing a suitable therapeutic strategy.
Methods
The data of 996 consecutive advanced gastric cancer patients who underwent gastrectomy between 1992 and 1998 at the National Cancer Center Hospital were retrospectively studied.
Results
The 2- and 5-year survival rates of the patients who underwent gastrectomy without any other noncurative factors besides Cy1 were 25.3 and 7.8%, respectively. When the analysis was limited to type 4 advanced gastric cancer patients, none of the patients with Cy1 survived for more than 40 months.
Conclusions
The prognosis of gastric cancer patients with Cy1 is very poor. Some patients show long survival after standard gastrectomy with D2 lymph node dissection; however, the prognosis of type 4 gastric cancer patients with Cy1 is so poor that multimodality therapy, including perioperative chemotherapy, is essential. |
| doi_str_mv | 10.1007/s00268-009-0355-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734289341</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734289341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5164-7fc517fdc3923c7eef027fb0c445fc39429e7e2994cf8f9ec458f399de2b075d3</originalsourceid><addsrcrecordid>eNqFkF9LHDEUxUOp1K31A_hShkLp09ibm2QyebSD2pYFC1Z8DNlMskRmZ2wyq-y3b4bZKgjFp5s_v3Nycgg5oXBKAeTXBIBVXQKoEpgQJX1DFpQzLJEhe0sWwCqe15Qdkvcp3QFQWUH1jhwigOCCswVprsO6Dz5Y01tXDL5YmgezdkWzG4duWO-K0Bdn7cN02xaXJo0x2KKZtrH4Zcbg-jF9IAfedMkd7-cRubk4_918L5dXlz-as2VpBc1BpM9T-tYyhcxK5zyg9CuwnAufDzkqJx0qxa2vvXKWi9ozpVqHK5CiZUfky-x7H4c_W5dGvQnJuq4zvRu2SUvGsVaM00x-ekHeDdvY53AaqVICgWKG6AzZOKQUndf3MWxM3GkKeupXz_3q3K-e-tWT8ce98Xa1ce2T4l-hGfi8B0yypvMxVxXSM4dcopB15tTMPYbO7V5_Wd_-vP52AVxWPGtx1qYs69cuPv_u_8n_AjL8oWc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219952012</pqid></control><display><type>article</type><title>Significance of Lavage Cytology in Advanced Gastric Cancer Patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>SpringerLink Journals</source><creator>Fukagawa, Takeo ; Katai, Hitoshi ; Saka, Makoto ; Morita, Shinji ; Sasajima, Yuko ; Taniguchi, Hirokazu ; Sano, Takeshi ; Sasako, Mitsuru</creator><creatorcontrib>Fukagawa, Takeo ; Katai, Hitoshi ; Saka, Makoto ; Morita, Shinji ; Sasajima, Yuko ; Taniguchi, Hirokazu ; Sano, Takeshi ; Sasako, Mitsuru</creatorcontrib><description>Background
Lavage cytology positive (Cy1) is well known as a poor prognostic factor in advanced gastric cancer patients. However, the optimal therapeutic strategy for patients with Cy1 has not yet been established. The aim of this study was to evaluate the clinical significance of Cy1 for the purpose of establishing a suitable therapeutic strategy.
Methods
The data of 996 consecutive advanced gastric cancer patients who underwent gastrectomy between 1992 and 1998 at the National Cancer Center Hospital were retrospectively studied.
Results
The 2- and 5-year survival rates of the patients who underwent gastrectomy without any other noncurative factors besides Cy1 were 25.3 and 7.8%, respectively. When the analysis was limited to type 4 advanced gastric cancer patients, none of the patients with Cy1 survived for more than 40 months.
Conclusions
The prognosis of gastric cancer patients with Cy1 is very poor. Some patients show long survival after standard gastrectomy with D2 lymph node dissection; however, the prognosis of type 4 gastric cancer patients with Cy1 is so poor that multimodality therapy, including perioperative chemotherapy, is essential.</description><identifier>ISSN: 0364-2313</identifier><identifier>EISSN: 1432-2323</identifier><identifier>DOI: 10.1007/s00268-009-0355-1</identifier><identifier>PMID: 20054543</identifier><identifier>CODEN: WJSUDI</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Abdominal Surgery ; Adjuvant Chemotherapy ; Advanced Gastric Cancer ; Biological and medical sciences ; Cardiac Surgery ; Gastrectomy - mortality ; Gastric Cancer ; Gastric Cancer Patient ; Gastric Lavage ; Gastroenterology. Liver. Pancreas. Abdomen ; General aspects ; General Surgery ; Humans ; Medical sciences ; Medicine ; Medicine & Public Health ; Neoplasm Invasiveness ; Preoperative Chemotherapy ; Retrospective Studies ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Stomach Neoplasms - therapy ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Surgery ; Survival Rate ; Thoracic Surgery ; Tumors ; Vascular Surgery</subject><ispartof>World journal of surgery, 2010-03, Vol.34 (3), p.563-568</ispartof><rights>Société Internationale de Chirurgie 2010</rights><rights>2010 The Author(s) under exclusive licence to Société Internationale de Chirurgie</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5164-7fc517fdc3923c7eef027fb0c445fc39429e7e2994cf8f9ec458f399de2b075d3</citedby><cites>FETCH-LOGICAL-c5164-7fc517fdc3923c7eef027fb0c445fc39429e7e2994cf8f9ec458f399de2b075d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00268-009-0355-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00268-009-0355-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,41467,42536,45553,45554,51298</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22472578$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20054543$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fukagawa, Takeo</creatorcontrib><creatorcontrib>Katai, Hitoshi</creatorcontrib><creatorcontrib>Saka, Makoto</creatorcontrib><creatorcontrib>Morita, Shinji</creatorcontrib><creatorcontrib>Sasajima, Yuko</creatorcontrib><creatorcontrib>Taniguchi, Hirokazu</creatorcontrib><creatorcontrib>Sano, Takeshi</creatorcontrib><creatorcontrib>Sasako, Mitsuru</creatorcontrib><title>Significance of Lavage Cytology in Advanced Gastric Cancer Patients</title><title>World journal of surgery</title><addtitle>World J Surg</addtitle><addtitle>World J Surg</addtitle><description>Background
Lavage cytology positive (Cy1) is well known as a poor prognostic factor in advanced gastric cancer patients. However, the optimal therapeutic strategy for patients with Cy1 has not yet been established. The aim of this study was to evaluate the clinical significance of Cy1 for the purpose of establishing a suitable therapeutic strategy.
Methods
The data of 996 consecutive advanced gastric cancer patients who underwent gastrectomy between 1992 and 1998 at the National Cancer Center Hospital were retrospectively studied.
Results
The 2- and 5-year survival rates of the patients who underwent gastrectomy without any other noncurative factors besides Cy1 were 25.3 and 7.8%, respectively. When the analysis was limited to type 4 advanced gastric cancer patients, none of the patients with Cy1 survived for more than 40 months.
Conclusions
The prognosis of gastric cancer patients with Cy1 is very poor. Some patients show long survival after standard gastrectomy with D2 lymph node dissection; however, the prognosis of type 4 gastric cancer patients with Cy1 is so poor that multimodality therapy, including perioperative chemotherapy, is essential.</description><subject>Abdominal Surgery</subject><subject>Adjuvant Chemotherapy</subject><subject>Advanced Gastric Cancer</subject><subject>Biological and medical sciences</subject><subject>Cardiac Surgery</subject><subject>Gastrectomy - mortality</subject><subject>Gastric Cancer</subject><subject>Gastric Cancer Patient</subject><subject>Gastric Lavage</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>General aspects</subject><subject>General Surgery</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Invasiveness</subject><subject>Preoperative Chemotherapy</subject><subject>Retrospective Studies</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach Neoplasms - therapy</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Thoracic Surgery</subject><subject>Tumors</subject><subject>Vascular Surgery</subject><issn>0364-2313</issn><issn>1432-2323</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkF9LHDEUxUOp1K31A_hShkLp09ibm2QyebSD2pYFC1Z8DNlMskRmZ2wyq-y3b4bZKgjFp5s_v3Nycgg5oXBKAeTXBIBVXQKoEpgQJX1DFpQzLJEhe0sWwCqe15Qdkvcp3QFQWUH1jhwigOCCswVprsO6Dz5Y01tXDL5YmgezdkWzG4duWO-K0Bdn7cN02xaXJo0x2KKZtrH4Zcbg-jF9IAfedMkd7-cRubk4_918L5dXlz-as2VpBc1BpM9T-tYyhcxK5zyg9CuwnAufDzkqJx0qxa2vvXKWi9ozpVqHK5CiZUfky-x7H4c_W5dGvQnJuq4zvRu2SUvGsVaM00x-ekHeDdvY53AaqVICgWKG6AzZOKQUndf3MWxM3GkKeupXz_3q3K-e-tWT8ce98Xa1ce2T4l-hGfi8B0yypvMxVxXSM4dcopB15tTMPYbO7V5_Wd_-vP52AVxWPGtx1qYs69cuPv_u_8n_AjL8oWc</recordid><startdate>201003</startdate><enddate>201003</enddate><creator>Fukagawa, Takeo</creator><creator>Katai, Hitoshi</creator><creator>Saka, Makoto</creator><creator>Morita, Shinji</creator><creator>Sasajima, Yuko</creator><creator>Taniguchi, Hirokazu</creator><creator>Sano, Takeshi</creator><creator>Sasako, Mitsuru</creator><general>Springer-Verlag</general><general>Springer‐Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>201003</creationdate><title>Significance of Lavage Cytology in Advanced Gastric Cancer Patients</title><author>Fukagawa, Takeo ; Katai, Hitoshi ; Saka, Makoto ; Morita, Shinji ; Sasajima, Yuko ; Taniguchi, Hirokazu ; Sano, Takeshi ; Sasako, Mitsuru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5164-7fc517fdc3923c7eef027fb0c445fc39429e7e2994cf8f9ec458f399de2b075d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Abdominal Surgery</topic><topic>Adjuvant Chemotherapy</topic><topic>Advanced Gastric Cancer</topic><topic>Biological and medical sciences</topic><topic>Cardiac Surgery</topic><topic>Gastrectomy - mortality</topic><topic>Gastric Cancer</topic><topic>Gastric Cancer Patient</topic><topic>Gastric Lavage</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>General aspects</topic><topic>General Surgery</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Invasiveness</topic><topic>Preoperative Chemotherapy</topic><topic>Retrospective Studies</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach Neoplasms - therapy</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Thoracic Surgery</topic><topic>Tumors</topic><topic>Vascular Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fukagawa, Takeo</creatorcontrib><creatorcontrib>Katai, Hitoshi</creatorcontrib><creatorcontrib>Saka, Makoto</creatorcontrib><creatorcontrib>Morita, Shinji</creatorcontrib><creatorcontrib>Sasajima, Yuko</creatorcontrib><creatorcontrib>Taniguchi, Hirokazu</creatorcontrib><creatorcontrib>Sano, Takeshi</creatorcontrib><creatorcontrib>Sasako, Mitsuru</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fukagawa, Takeo</au><au>Katai, Hitoshi</au><au>Saka, Makoto</au><au>Morita, Shinji</au><au>Sasajima, Yuko</au><au>Taniguchi, Hirokazu</au><au>Sano, Takeshi</au><au>Sasako, Mitsuru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Significance of Lavage Cytology in Advanced Gastric Cancer Patients</atitle><jtitle>World journal of surgery</jtitle><stitle>World J Surg</stitle><addtitle>World J Surg</addtitle><date>2010-03</date><risdate>2010</risdate><volume>34</volume><issue>3</issue><spage>563</spage><epage>568</epage><pages>563-568</pages><issn>0364-2313</issn><eissn>1432-2323</eissn><coden>WJSUDI</coden><abstract>Background
Lavage cytology positive (Cy1) is well known as a poor prognostic factor in advanced gastric cancer patients. However, the optimal therapeutic strategy for patients with Cy1 has not yet been established. The aim of this study was to evaluate the clinical significance of Cy1 for the purpose of establishing a suitable therapeutic strategy.
Methods
The data of 996 consecutive advanced gastric cancer patients who underwent gastrectomy between 1992 and 1998 at the National Cancer Center Hospital were retrospectively studied.
Results
The 2- and 5-year survival rates of the patients who underwent gastrectomy without any other noncurative factors besides Cy1 were 25.3 and 7.8%, respectively. When the analysis was limited to type 4 advanced gastric cancer patients, none of the patients with Cy1 survived for more than 40 months.
Conclusions
The prognosis of gastric cancer patients with Cy1 is very poor. Some patients show long survival after standard gastrectomy with D2 lymph node dissection; however, the prognosis of type 4 gastric cancer patients with Cy1 is so poor that multimodality therapy, including perioperative chemotherapy, is essential.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>20054543</pmid><doi>10.1007/s00268-009-0355-1</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0364-2313 |
| ispartof | World journal of surgery, 2010-03, Vol.34 (3), p.563-568 |
| issn | 0364-2313 1432-2323 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734289341 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; SpringerLink Journals |
| subjects | Abdominal Surgery Adjuvant Chemotherapy Advanced Gastric Cancer Biological and medical sciences Cardiac Surgery Gastrectomy - mortality Gastric Cancer Gastric Cancer Patient Gastric Lavage Gastroenterology. Liver. Pancreas. Abdomen General aspects General Surgery Humans Medical sciences Medicine Medicine & Public Health Neoplasm Invasiveness Preoperative Chemotherapy Retrospective Studies Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - therapy Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Surgery Survival Rate Thoracic Surgery Tumors Vascular Surgery |
| title | Significance of Lavage Cytology in Advanced Gastric Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T04%3A25%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Significance%20of%20Lavage%20Cytology%20in%20Advanced%20Gastric%20Cancer%20Patients&rft.jtitle=World%20journal%20of%20surgery&rft.au=Fukagawa,%20Takeo&rft.date=2010-03&rft.volume=34&rft.issue=3&rft.spage=563&rft.epage=568&rft.pages=563-568&rft.issn=0364-2313&rft.eissn=1432-2323&rft.coden=WJSUDI&rft_id=info:doi/10.1007/s00268-009-0355-1&rft_dat=%3Cproquest_cross%3E734289341%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219952012&rft_id=info:pmid/20054543&rfr_iscdi=true |